TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8138958

Group type: EXPERIMENTAL
Intervention: Morphine (20, 40 and 60 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (0.1 and 0.2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocine (45 and 60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 3202400

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31846499

Group type: EXPERIMENTAL
Intervention: rESWT on agonist muscles (B)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: rESWT on antagonist muscles (C)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (A)
Number of subjects: 82
Study: 29167951

Group type: EXPERIMENTAL
Intervention: Radioembolization (RE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bland hepatic arterial embolization (HAE)
Number of subjects: 11
Study: 28247424

Group type: EXPERIMENTAL
Intervention: Quick Drinking Screen (QDS)
Number of subjects: 472

Group type: COMPARATOR
Intervention: AUDIT-C
Number of subjects: 472
Study: 26413145

Group type: EXPERIMENTAL
Intervention: Schroth exercises plus standard of care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 50
Study: 23146410

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study: 20806703

Group type: EXPERIMENTAL
Intervention: Immediate preparation with resin AH26 sealer
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed preparation with resin AH26 sealer
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Immediate preparation with ZOE Dorifil sealer
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed preparation with ZOE Dorifil sealer
Number of subjects: 86
Study: 18338313

Group type: EXPERIMENTAL
Intervention: Quasi-imputation strategy for correlated ordinal responses
Number of subjects: 0
Study: 16168729

Group type: EXPERIMENTAL
Intervention: Attend color group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ignore group
Number of subjects: 2
Study: 12750624

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 5% (Exacyl) mouthwashes prescribed during and after surgery
Number of subjects: 40
Study: 10096932

Group type: EXPERIMENTAL
Intervention: VDD pacing at LV free-wall
Number of subjects: 18

Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 18

Group type: COMPARATOR
Intervention: RV pacing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LV pacing
Number of subjects: 18
Study: 8671343

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (35 micrograms ethinyl oestradiol and 1 mg norethindrone)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (50 micrograms ethinyl oestradiol and 1 mg norethindrone)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Danazol 800 mg/day
Number of subjects: 54
Study: 1751239

Group type: EXPERIMENTAL
Intervention: Short hour (SH) dialysis using AN69S plus volumetric control (VC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional (CNV) cellulosic non-VC dialysis
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Short hour (SH) dialysis
Number of subjects: 112
Study: 378729

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (160 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Propranolol (40 mg three times daily)
Number of subjects: 18
Study: 31590967

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing (IS) therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin-providing (IP) therapy
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (REV)
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Intensive medical therapy (MED)
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: IS therapy with REV
Number of subjects: 2368

Group type: COMPARATOR
Intervention: IP therapy with REV
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: IS therapy with MED
Number of subjects: 2368

Group type: COMPARATOR
Intervention: IP therapy with MED
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: IS therapy and REV in CABG preselected patients
Number of subjects: 2368
Study: 28195501

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) stress management programme
Number of subjects: 362

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study: 26313794

Group type: EXPERIMENTAL
Intervention: Ward nurse education
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control ward (no nurse education)
Number of subjects: 205
Study: 23552787

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composites
Number of subjects: 104

Group type: COMPARATOR
Intervention: Wire-ligation fixation
Number of subjects: 104
Study: 22310866

Group type: EXPERIMENTAL
Intervention: Standardized peristomal skin care (SPSC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Crusting technique (CT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both SPSC and CT
Number of subjects: 81
Study: 19583650

Group type: EXPERIMENTAL
Intervention: Distraction using kaleidoscopes
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 206
Study: 17407645

Group type: EXPERIMENTAL
Intervention: Torcetrapib/atorvastatin (T/A) - torcetrapib dose 60 mg, atorvastatin dose 20-80 mg (RADIANCE 1) or 10-80 mg (RADIANCE 2)
Number of subjects: 1656

Group type: COMPARATOR
Intervention: Atorvastatin alone - atorvastatin dose 20-80 mg (RADIANCE 1) or 10-80 mg (RADIANCE 2)
Number of subjects: 1656
Study: 15126715

Group type: EXPERIMENTAL
Intervention: 4 g x d of mixed CLA isomers for 8 wk
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 16
Study: 11228472

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 24
Study: 9512220

Group type: EXPERIMENTAL
Intervention: Gonadotrophin‐releasing hormone agonist (GnRHa) and human menopausal gonadotrophin (HMG)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG) only
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Dexamethasone administration
Number of subjects: 564

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 564
Study: 8069190

Group type: EXPERIMENTAL
Intervention: CHOP (n = 147)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: CHOP plus methotrexate (n = 46)
Number of subjects: 287

Group type: COMPARATOR
Intervention: CHOP (n = 44)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Intermittent chlorambucil plus prednisone (n = 140)
Number of subjects: 287
Study: 2460352

Group type: EXPERIMENTAL
Intervention: 3 x 75 MBq 89Sr
Number of subjects: 49
Study: 30861426

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Silver nitrate cauterization
Number of subjects: 100
Study: 27605543

Group type: EXPERIMENTAL
Intervention: Pharmacist review of all medication according to the Good Palliative‐Geriatric Practice algorithm and the Screening Tool of Older Person's Prescriptions‐Screening Tool to Alert Doctors to the Right Treatment
Number of subjects: 503

Group type: COMPARATOR
Intervention: Routine clinical practice
Number of subjects: 503
Study: 25162916

Group type: EXPERIMENTAL
Intervention: Infusion prepared from 2, 4, or 8 g of C. citratus leaves once daily for 30 days
Number of subjects: 105
Study: 22168624

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autogenous bone chips
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 21904641

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation at 1,200 mg daily for 7 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no NAC supplementation)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation
Number of subjects: 29
Study: 18089630

Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 898

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 898
Study: 17942871

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 10154

Group type: COMPARATOR
Intervention: Pap testing
Number of subjects: 10154

Group type: EXPERIMENTAL
Intervention: Both tests used together
Number of subjects: 10154

Group type: EXPERIMENTAL
Intervention: Triage procedures for Pap or HPV testing
Number of subjects: 10154
Study: 14506092

Group type: EXPERIMENTAL
Intervention: Interferon-gamma
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 13
Study: 11167642

Group type: EXPERIMENTAL
Intervention: Individual physiotherapy
Number of subjects: 530

Group type: COMPARATOR
Intervention: Group physiotherapy
Number of subjects: 530
Study: 9603667

Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on intact skin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on inflamed skin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Advantan lotion containing 0.1% methylprednisolone aceponate applied on stripped skin
Number of subjects: 6
Study: 7921293

Group type: EXPERIMENTAL
Intervention: Computer-based health maintenance tracking system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual flowchart-based tracking system
Number of subjects: 0
Study: 2965374

Group type: EXPERIMENTAL
Intervention: Treatment A: 8 mg/kg/day at 07.00 h and 4 mg/kg/day at 19.00 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment B: 6 mg/kg/day at 07.00 h and 6 mg/kg/day at 19.00 h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment C: 4 mg/kg/day at 07.00 h and 8 mg/kg/day at 19.00 h
Number of subjects: 12
Study: 31059974

Group type: EXPERIMENTAL
Intervention: Fulvestrant (Faslodex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 0
Study: 27856267

Group type: EXPERIMENTAL
Intervention: Stemless shoulder prosthesis (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard stem humeral head replacement (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 28537365

Group type: EXPERIMENTAL
Intervention: Fluoride varnish group
Number of subjects: 758

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 758
Study: 24642580

Group type: COMPARATOR
Intervention: Standard Triple Therapy (STT) - 10 days of treatment with esomeprazole, amoxicillin, and clarithromycin
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) - 5 days of esomeprazole and amoxicillin, followed by 5 days of esomeprazole, clarithromycin, and tinidazole
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with dual CLA-R and MET-R
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with isolated CLA-R
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sequential Therapy (SQT) with isolated MET-R
Number of subjects: 280
Study: 21748722

Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid (375 mg daily, titrated to 500, 750, and 1,000 mg as tolerated)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Extended-release nicotinic acid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19527380

Group type: EXPERIMENTAL
Intervention: Daily iron folic acid (Group I, n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Weekly iron folic acid (Group II, n = 30)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Daily iron (III)-hydroxide polymaltose complex (Group III, n = 30)
Number of subjects: 90
Study: 17966618

Group type: EXPERIMENTAL
Intervention: H2 blocker (famotidine 20 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study: 16238560

Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1) loading dose, 0.2 mg.kg(‐1) bolus doses)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine (0.1 mg.kg(‐1) loading dose, 0.02 mg.kg(‐1) bolus doses)
Number of subjects: 60
Study: 11883725

Group type: EXPERIMENTAL
Intervention: Exposure therapy alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both combined
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Post-treatment sense of control/internal attribution
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Baseline beliefs
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Improvement in beliefs
Number of subjects: 87
Study: 9579626

Group type: EXPERIMENTAL
Intervention: Titanium reinforced barrier membranes
Number of subjects: 15

Group type: COMPARATOR
Intervention: Connective tissue grafts
Number of subjects: 15
Study: 8131679

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1000-kcal meal
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stepwise distension
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intermittent distension
Number of subjects: 9

Group type: COMPARATOR
Intervention: Stepwise distension (IBS vs Controls)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intermittent distension (IBS vs Controls)
Number of subjects: 9
Study: 2573286

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 252

Group type: COMPARATOR
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 252
Study: 31852424

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 31233135

Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (TR) system, 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Number of subjects: 124

Group type: COMPARATOR
Intervention: In-clinic therapy (IC), 36 sessions of arm motor therapy plus stroke education, 70 minutes each session.
Number of subjects: 124
Study: 28043880

Group type: EXPERIMENTAL
Intervention: QLF technology combined with visual inspection
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional visual inspection alone (Control)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: QLF technology
Number of subjects: 92
Study: 25730649

Group type: EXPERIMENTAL
Intervention: WBV + RE
Number of subjects: 10

Group type: COMPARATOR
Intervention: RE only
Number of subjects: 10
Study: 23558158

Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 353

Group type: COMPARATOR
Intervention: Health Education (Control)
Number of subjects: 353
Study: 21418153

Group type: EXPERIMENTAL
Intervention: Opened mouth - sniffing position (OS)
Number of subjects: 40
Study: 18359872

Group type: EXPERIMENTAL
Intervention: Screening for nephropathy followed by treatment with irbesartan 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study: 16573708

Group type: EXPERIMENTAL
Intervention: Intra-vas device (IVD)
Number of subjects: 288

Group type: COMPARATOR
Intervention: No-scalpel vasectomy (NSV)
Number of subjects: 288
Study: 12705572

Group type: EXPERIMENTAL
Intervention: Referential condition (novel words or novel nonverbal sounds with social-referential interaction)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonreferential condition (novel words or novel nonverbal sounds emitted from a baby monitor)
Number of subjects: 2
Study: 10735784

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9014265

Group type: EXPERIMENTAL
Intervention: Classroom suicide response lessons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All students (both intervention and control)
Number of subjects: 0
Study: 1407927

Group type: EXPERIMENTAL
Intervention: Unilateral acupressure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral acupressure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 60
Study: 3906162

Group type: EXPERIMENTAL
Intervention: Travasorb‐Hepatic (BCAA rich supplement)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ensure (casein based supplement)
Number of subjects: 8
Study: 29573335

Group type: EXPERIMENTAL
Intervention: Belatacept more intense (MI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Belatacept less intense (LI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 100
Study: 26879752

Group type: EXPERIMENTAL
Intervention: Pneumatic cystolithotripsy (CL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Holmium: YAG laser cystolithotripsy (Ho:YAG CL)
Number of subjects: 25
Study: 24223416

Group type: EXPERIMENTAL
Intervention: Well adapted (WA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moderately well adapted (MA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Poorly adapted (PA)
Number of subjects: 24
Study: 22455412

Group type: EXPERIMENTAL
Intervention: Brodalumab 70 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 20737516

Group type: EXPERIMENTAL
Intervention: Mirtazapine (add-on treatment)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mirtazapine (during both phases)
Number of subjects: 39
Study: 18717105

Group type: EXPERIMENTAL
Intervention: Critical Appraisal techniques
Number of subjects: 0
Study: 15679722

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 400 microg nasal spray
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 100 microg nasal spray
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 200 microg nasal spray
Number of subjects: 165
Study: 14532926

Group type: EXPERIMENTAL
Intervention: RBC-C (ranitidine bismuth citrate 400 mg plus clarithromycin 500 mg)
Number of subjects: 305

Group type: COMPARATOR
Intervention: OCA (omeprazole 20 mg, clarithromycin 500 mg and amoxicillin 1000 mg)
Number of subjects: 305
Study: 10800385

Group type: EXPERIMENTAL
Intervention: Vacuum stabilizing system (Vacoped)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cast treatment
Number of subjects: 40
Study: 8774258

Group type: EXPERIMENTAL
Intervention: Controlled respiration at 10 breaths/min while supine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Controlled breathing while standing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Controlled respiration in normal subjects
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Respiration and change in posture
Number of subjects: 21
Study: 1419449

Group type: EXPERIMENTAL
Intervention: Open palm technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard single resuscitator ventilation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Two-resuscitator ventilation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open palm technique (small hands)
Number of subjects: 18
Study: 6724467

Group type: EXPERIMENTAL
Intervention: Oral theophylline therapy (193.2 mg Theophyllinmonohydrat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Systemic application (46.8 mg Aethylendiamin as Euphyllin)
Number of subjects: 10
Study: 29172716

Group type: EXPERIMENTAL
Intervention: Aircraft noise exposure (measured in dB(A))
Number of subjects: 1244
Study: 29863694

Group type: EXPERIMENTAL
Intervention: Mexidol (200 mg intravenously for 10 days, then 2 tablets 0.125 mg twice a day for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 42
Study: 26018456

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided IJV cannulation in children
Number of subjects: 37
Study: 24969786

Group type: EXPERIMENTAL
Intervention: Nurse-led communication support programme using a Question Prompt List (QPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22200763

Group type: EXPERIMENTAL
Intervention: Tegafur (1,000 mg/day for 5 days) + Lentinan (1 mg diluted in 250 ml normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tegafur (1,000 mg/day for 5 days)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tegafur + Lentinan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tegafur
Number of subjects: 50
Study: 20579633

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 108
Study: 18047871

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 12
Study: 16260972

Group type: EXPERIMENTAL
Intervention: Intravenous carbohydrate (CHO) load (20% dextrose solution) during exercise
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (CHO) load (carbohydrate‐rich meal) during exercise
Number of subjects: 14
Study: 12113564

Group type: EXPERIMENTAL
Intervention: 5 mg i.v. droperidol over 5 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: i.v. saline placebo
Number of subjects: 16
Study: 10726785

Group type: EXPERIMENTAL
Intervention: Fortified gentamicin ointment (1.5%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fortified gentamicin eye drops (1.5%)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both ointment and drops
Number of subjects: 15
Study: 9195026

Group type: EXPERIMENTAL
Intervention: Prilocaine 5% with adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pethidine 5% with adrenaline
Number of subjects: 20
Study: 1300856

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (0.5%, 1-1.5 mg kg-1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (150 micrograms)
Number of subjects: 28
Study: 3546148

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d.
Number of subjects: 45
Study: 31362729

Group type: EXPERIMENTAL
Intervention: Combination of flipped classroom with problem-based learning (CG)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Traditional lecture‐based classroom (TG)
Number of subjects: 74